Strategic Initiative

Slingshot members are tracking this corporate initiative:

Mannkind agrees to collaboration and license agreement with a newly formed entity, Receptor Life Science, to treat chronic pain, neurologic diseases and inflammatory disorders.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MNKD

50%

Additional Information

Additional Relevant Details
Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.
http://investors.man...
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jan 21, 2016
Projected Implementation:
Q1, 2016
Relevance Tracked Until:
Q1, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Collaboration, License Agreement, Chronic Pain, Neurologic Disease, Inflammatory Disorders